Literature DB >> 1673012

Amphotericin B for second-line treatment of Indian kala-azar.

M Mishra, M P Singh, D Choudhury, V P Singh, A B Khan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1673012     DOI： 10.1016/0140-6736(91)90268-t

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

1.  Improving outcome of treatment of kala-azar by supplementation of amphotericin B with physiologic saline and potassium chloride.

Authors:  Chandeshwar P Thakur; A Kumar; Dipendra K Mitra; Ambak Roy; Arun Kumar Sinha; Alok Ranjan
Journal:  Am J Trop Med Hyg       Date:  2010-11       Impact factor: 2.345

2.  Liposomal amphotericin B and leishmaniasis: dose and response.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  J Glob Infect Dis       Date:  2010-05

Review 3.  Therapeutic options for visceral leishmaniasis.

Authors:  Begoña Monge-Maillo; Rogelio López-Vélez
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

4.  Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide.

Authors:  Caspar J Hodiamont; Piet A Kager; Aldert Bart; Henry J C de Vries; Pieter P A M van Thiel; Tjalling Leenstra; Peter J de Vries; Michèle van Vugt; Martin P Grobusch; Tom van Gool
Journal:  PLoS Negl Trop Dis       Date:  2014-05-01

5.  Antileishmanial assessment of isoxazole derivatives against L. donovani.

Authors:  Sushobhan Mukhopadhyay; Dinesh S Barak; R Karthik; Sarvesh K Verma; Rabi S Bhatta; Neena Goyal; Sanjay Batra
Journal:  RSC Med Chem       Date:  2020-07-20

Review 6.  Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective.

Authors:  Om Prakash Singh; Bhawana Singh; Jaya Chakravarty; Shyam Sundar
Journal:  Infect Dis Poverty       Date:  2016-03-08       Impact factor: 4.520
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.